Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Prostatic Neoplasms 172Breast Neoplasms 24Neoplasms 13Leiomyoma 11Polycystic Ovary Syndrome 5Prostate Adenocarcinoma 3Neoplasm Metastasis 3Multiple Myeloma 3Lymphoma, Non-Hodgkin 3Adenocarcinoma 3Salivary Gland Neoplasms 2Rare Diseases 2Myofibroma 2Myelodysplastic Syndromes 2Leukemia, Myeloid, Acute 2Hodgkin Disease 2Breast Neoplasms, Male 2Uveal Melanoma 1Uterine Neoplasms 1Urogenital Neoplasms 1Stage I Prostate Adenocarcinoma AJCC v7 1Sleep Apnea, Obstructive 1Skin Neoplasms 1Skin Diseases 1Sexual Dysfunctions, Psychological 1Sexual Dysfunction, Physiological 1Salivary Gland Neoplasm Duct 1Respiratory Tract Diseases 1Recurrence 1Puberty, Precocious 1

Interventions

acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide 1Nivolumab 1Leuprolide 1Goserelin 1Docetaxel 1Androgen Antagonists 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Hormone Sensitive Prostate Cancer × Leuprolide × Clear all
NCT04126070 2026-05-27

Nivolumab + Docetaxel + ADT in mHSPC Patients With DDRD or Inflamed Tumors

Dana-Farber Cancer Institute

Phase 2 Active not recruiting
47 enrolled 16 charts
Genitourinary

Hormone Sensitive Prostate Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡